{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:24:38Z","timestamp":1777616678044,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jcv.2018.01.014","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T13:38:17Z","timestamp":1517405897000},"page":"44-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Prevalence of pre-treatment hepatitis C virus NS5A resistance associated amino-acid substitutions in genotype 1A infected patients in Scotland"],"prefix":"10.1016","volume":"101","author":[{"given":"Amanda","family":"Bradley-Stewart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alasdair","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory","family":"Gunson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2018.01.014_bib0005","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance\u2013 associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2018.01.014_bib0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update of hepatitis C resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jcv.2018.01.014_bib0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2018.01.014_bib0020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2018.01.014_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis c virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jcv.2018.01.014_bib0030","first-page":"1128A","article-title":"Baseline and post-baseline resistance analyses of phase 2\/3 studies of ledipasvir\/sofosbuvir \u00b1 RBV","volume":"60","author":"Sarrazin","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2018.01.014_bib0035","series-title":"66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)","article-title":"Prevalence of pre-treatment NS5A resistance associated variants in genotype 1 patients across different regions using deep sequencing and effect on treatment outcome with LDV\/SOF (Abstract 91)","author":"Zeuzem","year":"2015"},{"key":"10.1016\/j.jcv.2018.01.014_bib0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C","volume":"66","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2018.01.014_bib0045","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0168-8278(15)30976-4","article-title":"The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir\/sofosbuvir +\/_ RBV","volume":"62","author":"Sarrazin","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2018.01.014_bib0050","series-title":"Program and Abstracts of the 66th Annual Meeting of the American Association for the Study of Liver Diseases","article-title":"Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir\/grazoprevir (EBR\/GZR) against GT1a infection","author":"Jacobson","year":"2015"},{"key":"10.1016\/j.jcv.2018.01.014_bib0055","series-title":"ZEPATIER\u2019s Product Label","year":"2018"},{"key":"10.1016\/j.jcv.2018.01.014_bib0060","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/apt.13882","article-title":"The cost-effectiveness of testing for NS5a resistance associated polymorphisms at baseline in genotype 1a-infected (treatment-na\u00efve and treatment-experienced) subjects treated with all-oral elbasvir\/grazoprevir regimens in the United States","volume":"45","author":"Elbasha","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jcv.2018.01.014_bib0065","series-title":"HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C","year":"2017"},{"key":"10.1016\/j.jcv.2018.01.014_bib0070","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2018.01.014_bib0075","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AAC.00998-15","article-title":"Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2018.01.014_bib0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2018.01.014_bib0085","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3851\/IMP2729","article-title":"Virological escape in HCV genotype-1- infected patients receiving daclatasvir plus ribavirin and peginterferon alfa- 2a or alfa-2b","volume":"19","author":"McPhee","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2018.01.014_bib0090","unstructured":"NRES algorithm \u2013 requirements for REC review. Supplementary notes on research not requiring REC review, section 2. (August 2011)."},{"issue":"1","key":"10.1016\/j.jcv.2018.01.014_bib0095","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3851\/IMP2763","article-title":"Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naieve individuals infected with hepatitis C genotypes 1\u20134","volume":"20","author":"McCormick","year":"2015","journal-title":"Antivir. Ther."},{"issue":"6","key":"10.1016\/j.jcv.2018.01.014_bib0100","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/JCM.06689-11","article-title":"Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool","volume":"50","author":"Woods","year":"2012","journal-title":"Clin. Microbiol."},{"key":"10.1016\/j.jcv.2018.01.014_bib0105","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3851\/IMP2091","article-title":"Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor","volume":"17","author":"Plaza","year":"2012","journal-title":"Antivir. Ther."},{"issue":"3","key":"10.1016\/j.jcv.2018.01.014_bib0110","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/jac\/dku462","article-title":"NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus","volume":"70","author":"Peres-da-Silva","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2018.01.014_bib0115","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","article-title":"Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment","volume":"87","author":"Bartels","year":"2013","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.jcv.2018.01.014_bib0120","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1128\/AAC.01390-15","article-title":"Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir","volume":"59","author":"Liu","year":"2015","journal-title":"Agents Chemother."},{"issue":"9","key":"10.1016\/j.jcv.2018.01.014_bib0125","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/AAC.00763-16","article-title":"Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein","volume":"60","author":"Dvory-Sobol","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2018.01.014_bib0130","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the HCV NS5A inhibitors BMS-790052, in the in vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2018.01.014_bib0135","doi-asserted-by":"crossref","first-page":"S677","DOI":"10.1016\/S0168-8278(15)31094-1","article-title":"Resistance analysis of virologic failures in hepatitis C genotype 1 infected patients treated with grazoprevir\/ elbasvir +\/ _ ribavirin: the C-WORTHY study","volume":"62","author":"Black","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2018.01.014_bib0140","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","article-title":"NS5A inhibitors in the treatment of HCV","volume":"59","author":"Pawlotsky","year":"2013","journal-title":"J. Hepatol."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653218300246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653218300246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T10:29:29Z","timestamp":1535106569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653218300246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":28,"alternative-id":["S1386653218300246"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2018.01.014","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of pre-treatment hepatitis C virus NS5A resistance associated amino-acid substitutions in genotype 1A infected patients in Scotland","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2018.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}